Cardiovascular adverse events associated with smoking-cessation pharmacotherapies.
Publication/Presentation Date
1-1-2015
Abstract
Smoking continues to be the leading cause of preventable deaths in the USA, accounting for one in every five deaths every year, and cardiovascular (CV) disease remains the leading cause of those deaths. Hence, there is increasing awareness to quit smoking among the public and counseling plays an important role in smoking cessation. There are different pharmacological methods to help quit smoking that includes nicotine replacement products available over the counter, including patch, gum, and lozenges, to prescription medications, such as bupropion and varenicline. There have been reports of both nonserious and serious adverse CV events associated with the use of these different pharmacological methods, especially varenicline, which has been gaining media attention recently. Therefore, we systematically reviewed the various pharmacotherapies used in smoking cessation and analyzed the evidence behind these CV events reported with these therapeutic agents.
Volume
17
Issue
1
First Page
554
Last Page
554
ISSN
1534-3170
Published In/Presented At
Sharma, A., Thakar, S., Lavie, C. J., Garg, J., Krishnamoorthy, P., Sochor, O., Arbab-Zadeh, A., & Lichstein, E. (2015). Cardiovascular adverse events associated with smoking-cessation pharmacotherapies. Current cardiology reports, 17(1), 554. https://doi.org/10.1007/s11886-014-0554-8
PubMedID
25410148
Department(s)
Department of Medicine, Fellows and Residents
Document Type
Article